Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review.
Endocannabinoids
Ethanolamines
Humans
PEA
Pain
Pain management
Palmidrol
Palmitic acids
Palmitoylethanolamide
Systematic review
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
08 01 2019
08 01 2019
Historique:
received:
20
01
2018
accepted:
26
12
2018
entrez:
10
1
2019
pubmed:
10
1
2019
medline:
3
4
2020
Statut:
epublish
Résumé
Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions. A literature search will be performed using PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The population will be patients who have chronic pain, the intervention will be the administration of PEA alone or in combination with other drugs for the pain management; the comparison will be the standard therapy in accordance with the current guidelines for the treatment of pain. The Outcomes will be the reduction of pain not restricted to specific scales laying out the pain outcome data described in the included studies. This scoping review aims to describe the clinical applications of the PEA in chronic pain management and its outcome. Open Science Framework https://osf.io/74tmx/ .
Sections du résumé
BACKGROUND
Palmitoylethanolamide (PEA) belong to endocannabinoid family, a group of fatty acid amides. PEA has been proven to have analgesic and anti-inflammatory activity and has been used in several controlled studies focused on the management of chronic pain among adult patients with different underlying clinical conditions.
METHODS/DESIGN
A literature search will be performed using PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The population will be patients who have chronic pain, the intervention will be the administration of PEA alone or in combination with other drugs for the pain management; the comparison will be the standard therapy in accordance with the current guidelines for the treatment of pain. The Outcomes will be the reduction of pain not restricted to specific scales laying out the pain outcome data described in the included studies.
DISCUSSION
This scoping review aims to describe the clinical applications of the PEA in chronic pain management and its outcome.
SCOPING REVIEW REGISTRATION
Open Science Framework https://osf.io/74tmx/ .
Identifiants
pubmed: 30621775
doi: 10.1186/s13643-018-0934-z
pii: 10.1186/s13643-018-0934-z
pmc: PMC6323836
doi:
Substances chimiques
Amides
0
Anti-Inflammatory Agents, Non-Steroidal
0
Ethanolamines
0
Palmitic Acids
0
palmidrol
6R8T1UDM3V
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Références
Vet Immunol Immunopathol. 2010 Jan 15;133(1):9-15
pubmed: 19625089
Neurol Neurochir Pol. 2018 Jan - Feb;52(1):44-47
pubmed: 29157725
Br J Pharmacol. 2002 Oct;137(4):413-20
pubmed: 12359622
Br J Pharmacol. 2017 Jun;174(11):1349-1365
pubmed: 27539936
Brain Behav Immun. 2011 Aug;25(6):1099-112
pubmed: 21354467
Exp Neurol. 2010 Jul;224(1):48-55
pubmed: 20353771
Drugs Aging. 2017 Dec;34(12):941-952
pubmed: 29210011
J Biol Chem. 2000 Jan 7;275(1):605-12
pubmed: 10617657
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
BMC Anesthesiol. 2017 Dec 19;17(1):171
pubmed: 29258432
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
pubmed: 7724569
Biochem J. 2001 Aug 15;358(Pt 1):249-55
pubmed: 11485574
Arch Ital Urol Androl. 2017 Mar 31;89(1):17-21
pubmed: 28403589
Biochimie. 2010 Jun;92(6):724-7
pubmed: 20096327
J Pharmacol Exp Ther. 2008 Jul;326(1):12-23
pubmed: 18367664